A new analysis of four large European trials of cutaneous melanoma patients showed a substantial survival advantage for women, most likely explained by underlying biologic differences.
The addition of sorafenib to isolated limb infusion therapy with melphalan did not improve responses in a new phase I trial of patients with in-transit extremity melanoma.
Melanoma has become the poster cancer for genomic research. The identification of a driver mutation in the BRAF gene found in approximately 40% of metastatic melanoma patients and the subsequent approval last year of the targeted BRAF inhibitor, vemurafenib, has resulted in a surge of both clinical and laboratory research.
A new study from the National Cancer Institute shows that physical activity is associated with lower mortality rates in patients with breast and colon cancers.
An abstract presented at the 13th Annual Meeting of the American Society of Breast Surgeons suggests that women who are at high risk for recurrence may not need a mastectomy.
New data presented at the 13th Annual Meeting of the American Society of Breast Surgeons shows radiofrequency ablation can prevent local breast cancer recurrence just as effectively as radiation therapy. Compared to radiation therapy, radiofrequency ablation showed superior cosmetic results and poses little risk to healthy tissue.
Maintenance therapy with bevacizumab following combination therapy with bevacizumab, pemetrexed, and carboplatin could be an effective treatment for patients with advanced, nonsquamous non-small-cell lung cancer (NSCLC), according to a new study.
The American Lung Association recently released new guidelines for lung cancer screening, recommending low-dose computed tomography screening in high-risk smokers.
A study published today shows that whole-breast irradiation fares better than brachytherapy for women with breast cancer.
In a multicenter phase III trial of 360 patients with muscle-invasive bladder cancer, synchronous chemoradiotherapy provided better locoregional control without significant added toxicity, investigators for the Bladder Cancer 2001 trial have found.